Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

30, missing market expectations of 238 million pounds, while sales of shingles vaccine, Shingrix, fell 7% to 739 million pounds, also below estimates in a company compiled consensus. Walmsley told ...

He’ll examine Shingrix's real-world effectiveness in preventing HZ infection while estimating the vaccine’s effectiveness in preventing incident dementia and other adverse cognitive and neurological ...

“These data support our efforts to bring a new shingles vaccine to global markets,” stated George Simeon, Curevo’s Chief Executive Officer. “Though somewhat unsurprising, given amezosvatein also ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

-- Positive data from 876-patient head-to-head trial versus Shingrix ® shows amezosvatein elicits robust humoral and cellular immune responses with comparatively lower reactogenicity ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

Adults should discuss with their doctors about whether this vaccine is necessary. It is recommended that adults 50 and older receive two doses of Shingrix, the shingles vaccine, two to six months ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.